Temperature affects the susceptibility of Cryptococcus neoformans biofilms to antifungal agents

References

• Casadevall A, Perfect JR. Cryptococcus neoformans. Washington DC: ASM, 1998.
   Google Scholar
• Ma H, May RC. Virulence in Cryptococcus species. Adv Appl Microbiol 2009; 67: 131–190.
   PubMed Web of Science ®Google Scholar
• Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515–548.
   PubMed Web of Science ®Google Scholar
• Alspaugh JA, Perfect JR, Heitman J. Signal transduction pathways regulating differentiation and pathogenicity of Cryptococcus neoformans. Fung Genet Biol 1998; 25: 1–14.
   PubMedGoogle Scholar
• Jung WH, Sham A, White R, Kronstad JW. Iron regulation of the major virulence factors in the AIDS-associated pathogen Cryptococcus neoformans. PLoS Biol 2006; 4: e410–
   Google Scholar
• Jacobson ES, Emery HS. Temperature regulation of the cryptococcal phenoloxidase. J Med Vet Mycol 1991; 29: 121–124.
   PubMedGoogle Scholar
• Kuhn LR. Effect of elevated body temperatures on cryptococcosis in mice. Proc Soc Exp Biol Med 1949; 71: 341–343.
   PubMed Web of Science ®Google Scholar
• Steen BR, Lian T, Zuyderduyn S, . Temperature-regulated transcription in the pathogenic fungus Cryptococcus neoformans. Genome Res 2002; 12: 1386–1400.
   PubMed Web of Science ®Google Scholar
• Kraus PR, Boily MJ, Giles SS, . Identification of Cryptococcus neoformans temperature-regulated genes with a genomic-DNA microarray. Euk Cell 2004; 3: 1249–1260.
   PubMedGoogle Scholar
• Silva LKR, Staats CC, Goulart LS, . Identification of novel temperature-regulated genes in the human pathogen Cryptococcus neoformans using representational difference analysis. Res Microbiol. 2008; 159: 221–229.
   PubMedGoogle Scholar
• Walsh TJ, Schlegel R, Moody MM, Costerton JW, Salcman M. Ventriculoatrial shunt infection due to Cryptococcus neoformans: an ultrastructural and quantitative microbiological study. Neurosurg. 1986; 18: 373–375.
   PubMed Web of Science ®Google Scholar
• Bauters TGM, Swinne D, Stove V, Nelis HJ. Detection of single cells of Cryptococcus neoformans in clinical samples by solid-phase cytometry. J Clin Microbiol 2003; 41: 1736–1737.
   PubMedGoogle Scholar
• Chandra J, Kuhn DM, Mukherjee PK, . Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385–5394.
   PubMed Web of Science ®Google Scholar
• Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science. 1999; 284: 1318–1322.
   PubMed Web of Science ®Google Scholar
• Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995; 39: 2128–2131.
   PubMed Web of Science ®Google Scholar
• Repp KK, Menor SA, Pettit RK. Microplate Alamar blue assay for susceptibility testing of Candida albicans biofilms. Med Mycol 2007; 45: 603–607.
   PubMed Web of Science ®Google Scholar
• Martinez LR, Casadevall A. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 2006; 50: 1021–1033.
   PubMed Web of Science ®Google Scholar
• Di Bonaventura G, Pompilio A, Picciani C, . Biofilm formation by the emerging fungal pathogen Trichosporon asahii: Development, architecture, and antifungal resistance. Antimicrob Agents Chemother. 2006; 50: 3269–3276.
   PubMed Web of Science ®Google Scholar
• Doering TL. A unique α-1,3 mannosyltransferase of the pathogenic fungus Cryptococcus neoformans. J Bact 1999; 181: 5482–5488.
   PubMedGoogle Scholar
• Chung S, Mondon P, Chang YC, Kwon-Chung KJ. Cryptococcus neoformans with a mutation in the tetratricopeptide repeat-containing gene, CCN1, causes subcutaneous lesions but fails to cause systemic infection. Infect Immun. 2003; 71: 1988–1994.
   PubMedGoogle Scholar
• Clinical Laboratory Standards Institute. Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard M27-A2 2nd. Wayne, PA: Clinical Laboratory Standards Institute, 2002.
   Google Scholar
• Jacobson ES, Tingler MJ. Strains of Cryptococcus neoformans with defined capsular phenotypes. J Vet Mycol 1994; 32: 401–404.
   PubMedGoogle Scholar
• Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 1982; 15: 535–537.
   PubMed Web of Science ®Google Scholar
• Carrillo-Muñoz AJ, Quindos G, Tur C, . In vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother 1999; 44: 397–401.
   PubMed Web of Science ®Google Scholar
• Jin Y, Yip HK, Samaranayake H, Yau JY, Samaranayake LP. Biofilm-forming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J Clin Microbiol 2003; 41: 2961–2967.
   PubMed Web of Science ®Google Scholar
• Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70: 878–888.
   PubMed Web of Science ®Google Scholar
• Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002; 46: 1773–1780.
   PubMed Web of Science ®Google Scholar
• Ramage G, VandeWalle K, Bachman SP, Wickes BL, López-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. J Antimicrob Chemother 2002; 46: 3634–3636.
   Google Scholar
• Ramage G, VandeWalle K, Wickes BL, López-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother. 2001; 45: 2475–2479.
   PubMed Web of Science ®Google Scholar
• Zaragoza O, Frasés S, Casadevall A. Pathogenicity of Cryptococcus neoformans: an evolutionary perspective. Baquerro F, Nombela C, Cassell GH, Gutiérrez JA. Evolutionary Biology of Bacterial and Fungal Pathogens Washington, DC: ASM Press, 2008; 581–590.
   Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL, . Results from the ARTEMIS DISK global antifungal surveillance study, 1997–2007: 10.5 year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47: 117–123.
   PubMed Web of Science ®Google Scholar
• Thompson III GR, Wiederhold NP, Fothergill AW. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2009; 53: 309–311.
   PubMed Web of Science ®Google Scholar
• Liu OW, Chun CD, Chow ED. Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans. Cell 2008; 135: 174–188.
   PubMed Web of Science ®Google Scholar
• Block ER, Jennings AE, Bennett JE. Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Antimicrob Agents Chemother 1973; 4: 392–395.
   PubMedGoogle Scholar
• Peng T, Galgiani JN. In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother 1993; 37: 2126–2131.
   PubMed Web of Science ®Google Scholar
• Martinez LR, Casadevall A. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun 2005; 73: 6350–6362.
   PubMed Web of Science ®Google Scholar